antiplatelet drugs, aspirin
DISEASE INTERVENTION COMPARISON RESULTS
BMJ. 2002 Jan 12;324(7329):71-86 Meta-Analysis
IN atherosclerosis, coronary disease, ischemic stroke, peripheral arterial disease The Use of
antiplatelet drugs, aspirin, low-dose (75-150 mg/d), adenosine diphosphate (ADP) receptor inhibitors, clopidogrel
As Treatment, Chronic
Is better Than
placebo
To reduce recurrence of ischemic coronary and cerebral events, with absolute reductions of 3 to 4%, depending on specific conditions
Canadian Agency for Drugs and Technologies in Health - CADTH. 2013 Mar: 1(1B); 1-142 Systematic Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, antiplatelet drugs, aspirin, clopidogrel
As Treatment, Chronic
Is equal Than
anticoagulants, antivitamine K, warfarin, aspirin
To modify stroke, embolism or bleedings : there are some differences in some cases but with little absolute risk reduction
Stroke. 2000 Jun;31(6):1240-9 Meta-Analysis
IN stroke, ischemic, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin
As Treatment, Acute
Is better Than
placebo
To reduce early death or recurrent stroke (either ischemic or haemorrhagic): 8.2% aspirin versus 9.1% placebo.
Lancet. 1997 Jun 7;349(9066):1641-1649 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin
As Treatment, Acute
Is better Than
placebo
To reduce death at 1 month: 3.3% with aspirin VS 3.9% placebo
Lancet. 1997 May 31;349(9065):1569-1581 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin 300 mg/d
As Treatment, Acute
Is better Than
placebo or unfractionated heparin (UFH), either low or full-dose
To reduce at 14 days recurrent ischaemic strokes (2.8% aspirin VS 3.9% placebo) or death plus non-fatal recurrent stroke (11.3% aspirin vs 12.4% placebo)
J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1218-23 Meta-Analysis
IN stroke, ischemic, transient ischemic attack, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin plus dipyridamole combined
As Treatment, Chronic
Is better Than
aspirin alone
To reduce recurrent stroke (HR 0.78) and cardiovascular events (HR 0.82)
Stroke. 2008 Apr;39(4):1358-63 Meta-Analysis
IN stroke, ischemic, transient ischemic attack, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin, dipyridamole
As Treatment, Chronic
Is better Than
aspirin alone
To reduce cardivascular events (stroke, myocardial infarction, or vascular death): RR 0.77
Arch Surg. 2009 Jan;144(1):69-76 Review (Narrative)
IN surgical risk, haemorrhagic risk, antiplatelet drugs The Use of
antiplatelet drugs, aspirin, clopidogrel, perioperative use
As Treatment, Acute
Is better Than
withdraw aspirin
To avoid cardiovascular events: 10% risk if antiplatelet drugs withdawn. Aspirin should be maintained. Clopidogrel should be stopped, except if recent drug-eluting stent implantation.
Eur Heart J. 2008 Apr;29(8):1057-71 Meta-Analysis
IN surgical risk, haemorrhagic risk, aspirin, cardiac surgery The Use of
antiplatelet drugs, aspirin, pre-operative use
As Treatment, Acute
Is worse Than
placebo
To haemorrhage: pre-operative aspirin increased post-operative bleeding (Mean difference, 104.9 mL) and reoperation (OR 2.52)